SGLT-2 inhibitors reduce adverse CV events associated with restenosis in stents in patients with type 2 diabetes.

Published Date: 13 Mar 2023

Italy: Treatment with SGLT2 inhibitors in patients with type 2 diabetes (T2D) is associated with a reduced risk of restenosis in the stent...

Read Full News

Latest News

Oral Semaglutide May Reduce Heart Failure Risk in Patients With T2D

Oral Semaglutide May Reduce Heart Failure Risk in Patients With T2D

VESPER-3: Positive Results of Long-Term GLP-1 PF’3944 in Overweight and Obesity Without T2D

VESPER-3: Positive Results of Long-Term GLP-1 PF’3944 in Overweight and Obesity Without T2D

Obesity Prevalence in US Increasing Drastically, Expected to Continue into 2035

Obesity Prevalence in US Increasing Drastically, Expected to Continue into 2035

Genentech Reports Positive Results from Phase 2 Trial of CT-388 in Obesity

Genentech Reports Positive Results from Phase 2 Trial of CT-388 in Obesity

Finerenone Marks a Breakthrough for Kidney Protection in Type 1 Diabetes, with Janet McGill, MD, MA Janet McGill, MD, MA

McGill emphasizes new exciting data shared at ACR 2025.

FDA Approves Updated Starting Dose Guidelines for Inhaled Insulin Powder (Afrezza)

FDA Approves Updated Starting Dose Guidelines for Inhaled Insulin Powder (Afrezza)

Todays Updates

Phase 3b RESHAPE Study Evaluates Risk–Benefit of Switching From Ocrelizumab to BTK Inhibitor Remibrutinib Isabella Ciccone, MPH

A phase 3b study presented at ACTRIMS 2026 is evaluating whether switching to remibrutinib offers efficacy and safety comparable to continued ocrelizumab treatment in relapsing multiple sclerosis.

Todays Updates

Phase 3b RESHAPE Study Evaluates Risk–Benefit of Switching From Ocrelizumab to BTK Inhibitor Remibrutinib Isabella Ciccone, MPH

A phase 3b study presented at ACTRIMS 2026 is evaluating whether switching to remibrutinib offers efficacy and safety comparable to continued ocrelizumab treatment in relapsing multiple sclerosis.

Latest News

Oral Semaglutide May Reduce Heart Failure Risk in Patients With T2D

VESPER-3: Positive Results of Long-Term GLP-1 PF’3944 in Overweight and Obesity Without T2D

Obesity Prevalence in US Increasing Drastically, Expected to Continue into 2035

Genentech Reports Positive Results from Phase 2 Trial of CT-388 in Obesity

McGill emphasizes new exciting data shared at ACR 2025.

FDA Approves Updated Starting Dose Guidelines for Inhaled Insulin Powder (Afrezza)

News All Time

HCPLive 5 Stories in Under 5: Week of 12/28

HCPLive 5 Stories in Under 5: Week of 12/28

Weight-Adjusted Waist Index Predicts Cardiovascular Risk in Patients with T2D

Weight-Adjusted Waist Index Predicts Cardiovascular Risk in Patients with T2D

10 FDA Headlines You Missed in December 2025

10 FDA Headlines You Missed in December 2025

Endocrinology in 2025: Year in Review

Endocrinology in 2025: Year in Review

FDA Issues Complete Response Letter for Relacorilant for Hypercortisolism

FDA Issues Complete Response Letter for Relacorilant for Hypercortisolism

Hormonal Disorders in 2025: Year in Review

Hormonal Disorders in 2025: Year in Review

Type 2 Diabetes in 2025: Year in Review

Type 2 Diabetes in 2025: Year in Review

Impacts of the Lancet Commission on Obesity Treatment, With Pooja Singhal, MD

Impacts of the Lancet Commission on Obesity Treatment, With Pooja Singhal, MD

Gestational Diabetes Linked to Reduced Lung Function in Children

Gestational Diabetes Linked to Reduced Lung Function in Children

GLP-1 RA Use Linked to 42% Hepatocellular Carcinoma Risk Reduction in T2DM

GLP-1 RA Use Linked to 42% Hepatocellular Carcinoma Risk Reduction in T2DM

Orforglipron Maintains Weight Loss in Patients Switching from Semaglutide or Tirzepatide

Orforglipron Maintains Weight Loss in Patients Switching from Semaglutide or Tirzepatide

5 Endocrinology Headlines You Missed in November 2025

5 Endocrinology Headlines You Missed in November 2025

5 FDA Headlines You Missed in November 2025

5 FDA Headlines You Missed in November 2025

Metformin Fails to Improve Insulin Resistance in Type 1 Diabetes

Metformin Fails to Improve Insulin Resistance in Type 1 Diabetes

Beyond Blood Sugar: Reframing Diabetes Awareness Through the Lens of Obesity

Beyond Blood Sugar: Reframing Diabetes Awareness Through the Lens of Obesity

Semaglutide Provides Cardiorenal Benefits in CKD With or Without Diabetes

Semaglutide Provides Cardiorenal Benefits in CKD With or Without Diabetes

Recommended News For You

Survival rates for incurable larynx cancer investigated for first time

Liver cancer survival rates reflect income disparities

In R/R Follicular Lymphoma, Tisa-Cel Produces Long-Lasting Responses.

Nasal therapeutic HPV vaccine could prevent cervical cancer

New drug resistance mechanism in melanoma leptomeningeal disease revealed by study.

Novel radiotracer identifies biomarker for triple-negative breast cancer

Researchers found that patients undergoing chemotherapy had a higher risk of mixed infections and should begin antibiotic therapy right away.

Recommended Articles For You

Beyond the Tumor: Emerging Frontiers in Cancer Systems Biology 

Biomimetic Nanovesicles Target Senescent-Escape Cancer Stem Cells in Breast Cancer 

Advancements in Cancer Treatment and Survival Outcomes for Acute Myeloid Leukemia 

Unlocking the Potential of SCD: A Comprehensive Guide to Diagnosis and Treatment 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Research indicates that extended PSMA therapy is safe and effective for patients with prostate cancer.

2.

New research points out a promising strategy for treating metastatic medulloblastoma

3.

The Kansas Cancer Center awarded two Indian American doctors professorships.

4.

Patients face high out-of-pocket costs after incident cancer diagnosis

5.

A Lot Can Be Said About You by Including Yourself in Photos.

1.

Unlocking the Secrets of Ringed Sideroblasts: A New Frontier in Hematology

2.

The Latest Research on Acute Promyelocytic Leukemia: Advancements in Diagnosis and Therapy 

3.

Oncolytic Viruses in Breast Cancer: Unlocking Synergy with Novel Combination Therapies

4.

Unleashing the Oncolytic Arsenal: Talimogene Laherparepvec Monotherapy – A Targeted Cancer Immunotherapy Treatment

5.

Multidisciplinary Insights into Diagnosis, Management, and Outcomes in Oncology

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part IV

2.

First Line Combination Therapy- The Overall Survival Data in NSCLC Patients

3.

Efficient Management of First line ALK-rearranged NSCLC - Part VII

4.

Navigating the Complexities of Ph Negative ALL - Part XVI

5.

Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Continuation

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot